LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients - Wikidata - awgldk - TriplyDB

LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients

LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients

http://www.wikidata.org/entity/Q34220979

about

Novel Molecular Markers for Breast Cancer Targeting the Tumor Microenvironment: The Protumor Effects of IL-17 Related to Cancer Type Metformin as a new anti-cancer drug in adrenocortical carcinoma Too much cleavage of cyclin E promotes breast tumorigenesis.Components of the canonical and non-canonical Wnt pathways are not mis-expressed in pituitary tumors Tanshinone IIA inhibits HIF-1α and VEGF expression in breast cancer cells via mTOR/p70S6K/RPS6/4E-BP1 signaling pathway.Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence.Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers.IL-17A and its homologs IL-25/IL-17E recruit the c-RAF/S6 kinase pathway and the generation of pro-oncogenic LMW-E in breast cancer cells.Pediatric glioma-associated KIAA1549:BRAF expression regulates neuroglial cell growth in a cell type-specific and mTOR-dependent manner.Mesenchymal and stem-like cell properties targeted in suppression of chronically-induced breast cell carcinogenesis Cyclin E Associates with the Lipogenic Enzyme ATP-Citrate Lyase to Enable Malignant Growth of Breast Cancer Cells.Cytoplasmic Cyclin E and Phospho-Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast Cancer Hbo1 is a cyclin E/CDK2 substrate that enriches breast cancer stem-like cells.Pathogenesis and heterogeneity of ovarian cancer.Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer.AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers.Cyclin E2 is the predominant E-cyclin associated with NPAT in breast cancer cells Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer.Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer.

P2860

Q26753160-1D3D3A05-595D-42CC-BF1D-3A4F98CFDFB7 Q28066522-00DF5C29-AE22-4409-93CC-CEACF118FA88 Q28468634-8E05EFBF-AC3B-4978-8224-B619C1EAAA5F Q34221065-1658A44B-2C2E-4537-B8DC-6C66A351EE59 Q34701446-698E3F56-FDDA-4B3A-B7A1-DDEAAA5D74A3 Q35058837-220F1D1B-3E3B-4621-B1C4-D1F8EC51F8B0 Q35079179-988A002E-17A9-43EF-8B60-049BB4578BBC Q35897417-B50777D8-0DB9-461E-BF55-9D19AE90597E Q36288515-017E358B-7F80-4450-A2E5-26930D061CFB Q36464991-1C246229-2B2D-44A4-BB00-8433BD7160FE Q36772254-CCCC175D-7864-4AC7-B3B9-0EDBB1809DC3 Q36918276-3ACD4982-FB01-4023-AF7E-940BA428C40A Q37057171-85E34A1A-5591-44CD-A99D-BB2B104F18F9 Q37172133-CE3657A3-9919-4890-902D-0CE89EAEE10D Q37546692-DAD54D5B-9ED8-4286-AF37-FD69CFCB06B7 Q37716464-88D976F2-53A9-4681-8E38-8E13E899480F Q38743594-7A98ACE0-E7AE-488D-A2E7-7AEB3E2067D7 Q41874772-96AB680B-3B97-484B-A37C-C7F13DA43A39 Q49558301-508DDFAC-F517-40E7-B0C4-21790DA554C6 Q52955581-049A0FA0-4F8B-477C-A857-163D25218446

P2860

LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients

http://www.wikidata.org/entity/Q34220979

description

2012 nî lūn-bûn

@nan

2012 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մարտին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

LMW-E/CDK2 deregulates acinar ...... hway in breast cancer patients

@ast

LMW-E/CDK2 deregulates acinar ...... hway in breast cancer patients

@en

LMW-E/CDK2 deregulates acinar ...... hway in breast cancer patients

@nl

type

label

LMW-E/CDK2 deregulates acinar ...... hway in breast cancer patients

@ast

LMW-E/CDK2 deregulates acinar ...... hway in breast cancer patients

@en

LMW-E/CDK2 deregulates acinar ...... hway in breast cancer patients

@nl

prefLabel

LMW-E/CDK2 deregulates acinar ...... hway in breast cancer patients

@ast

LMW-E/CDK2 deregulates acinar ...... hway in breast cancer patients

@en

LMW-E/CDK2 deregulates acinar ...... hway in breast cancer patients

@nl

P1433

Q34220979-3C606594-23EB-41E9-A4A5-EC61929BA336

P1476

Q34220979-1978C0EF-19B5-4CC7-9ECF-19F555B7A7CC

P2093

Q34220979-17D26D39-3241-44C1-A24D-CDE4C59C4872

Q34220979-4DF902E7-FEFD-4EC6-A6BA-6A016D51A949

Q34220979-63EC95E8-C643-4FAD-B714-9FF968B489C9

Q34220979-6F351444-0E50-4149-91D9-FDFA74F45F19

Q34220979-73C2B7FA-0978-4357-B1A5-D9FE47AD6051

Q34220979-791998B8-452C-4157-8AF1-786307FA3589

Q34220979-AD6442FB-DEBE-436B-91CE-D1E8ECC2F882

Q34220979-D7DB9FCE-1823-4059-B887-481D6E49F4E0

Q34220979-DD3E3D15-B3C5-416E-84B0-91B385491993

Q34220979-F0E29D60-CDB2-4C63-8030-AB39A2FEBAE5

P2860

Q34220979-08AD0866-1859-4C53-8299-CE01F99018C3

Q34220979-099C4260-7882-44F9-AF8D-D25318D51A6F

Q34220979-0DF77ECB-72D5-4CEF-A5F4-98AA452B44C7

Q34220979-2EB499CA-F234-4E07-BB00-6CBA4CDF6925

Q34220979-30D3A4F0-8ECB-4C93-88E6-201001BD87F8

Q34220979-340FA440-D5FA-4740-8A00-EB6A22D7A7F2

Q34220979-360D9E65-16B5-4EAF-8C4B-7A2B6586CE4B

Q34220979-3683C458-17EA-4412-A561-1EC4815D92BD

Q34220979-3E494FF3-A1A7-46EB-BA5F-A2A88B5ABCD7

Q34220979-41732AC8-DDFF-4B76-9B5B-4A776CA1C01C

P304

Q34220979-33C186B2-11B8-4111-A4CE-74B5AF24C34D

P31

Q34220979-2D3656C1-4A6E-48A0-8C96-D1A4E3CA488A

P356

Q34220979-731F31B3-A046-4E28-BB0C-DEBAA6655D7F

P433

Q34220979-C3DE3614-9B43-4726-82CA-992EEB496B7D

P478

Q34220979-C8B33C84-7261-4722-BA6A-7853A9F97FA2

P577

Q34220979-6F17127B-BF9D-4BAA-A644-2FB8EB8E80C5

P5875

Q34220979-9BCD964F-5508-4562-B157-7282DDAAC3B3

P698

Q34220979-714EBB3F-EF1B-4CF8-8981-D3B5A492ED96

P921

Q34220979-9E6A5C37-D32D-4950-8238-85839AC86BC4

P932

Q34220979-B060034D-3E10-4E71-9D6E-1E9BDE0BF2C8

P356

JOURNAL.PGEN.1002538

P1433

P1476

LMW-E/CDK2 deregulates acinar ...... hway in breast cancer patients

@en

P2093

Caimiao Wei

http://www.w3.org/2001/XMLSchema#string

Gordon B Mills

http://www.w3.org/2001/XMLSchema#string

Hannah F Wingate

http://www.w3.org/2001/XMLSchema#string

Kelly K Hunt

http://www.w3.org/2001/XMLSchema#string

Khandan Keyomarsi

http://www.w3.org/2001/XMLSchema#string

Min Yi

http://www.w3.org/2001/XMLSchema#string

MyLinh T Duong

http://www.w3.org/2001/XMLSchema#string

Said Akli

http://www.w3.org/2001/XMLSchema#string

Wenbin Liu

http://www.w3.org/2001/XMLSchema#string

Yiling Lu

http://www.w3.org/2001/XMLSchema#string

P2860

Cyclins as markers of tumor proliferation: immunocytochemical studies in breast cancer

Nonparametric Estimation from Incomplete Observations

Cyclin E and survival in patients with breast cancer.

Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle

Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1

Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics

Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures

The third dimension bridges the gap between cell culture and live tissue

The MAPK(ERK-1,2) pathway integrates distinct and antagonistic signals from TGFalpha and FGF7 in morphogenesis of mouse mammary epithelium.

Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasets

P304

e1002538

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PGEN.1002538

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2012-03-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

223987298

http://www.w3.org/2001/XMLSchema#string

P698

22479189

http://www.w3.org/2001/XMLSchema#string

P921

P932

3315462

http://www.w3.org/2001/XMLSchema#string